6-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non–Small Cell Lung Cancer: Randomized I-SABR Trial
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S39-S40
DOI: 10.1016/j.ijrobp.2026.06.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von J.Y. Chang und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Chang, J., Lin, S., Dong, W., Liao, Z., Maguire, R., Gandhi, S., Gay, C., Zhang, J., Chun, S., Elamin, Y., Blumenschein, G., Cascone, T., Altan, M., Mehran, R., Chen, A., Balter, P., Wu, J., Lee, J., Sharma, P., & Heymach, J. (2026). 6-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non–Small Cell Lung Cancer: Randomized I-SABR Trial. International Journal of Radiation Oncology*Biology*Physics, 126(1), S39-S40. https://doi.org/10.1016/j.ijrobp.2026.06.010
Vancouver
Chang J, Lin S, Dong W, Liao Z, Maguire R, Gandhi S, et al. 6-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non–Small Cell Lung Cancer: Randomized I-SABR Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S39-S40. doi:10.1016/j.ijrobp.2026.06.010
BibTeX
@article{Chang2026,
author = {Chang, J.Y. and Lin, S.H. and Dong, W. and Liao, Z. and Maguire, R. and Gandhi, S. and Gay, C.M. and Zhang, J. and Chun, S.G. and Elamin, Y. and Blumenschein, G.R. and Cascone, T. and Altan, M. and Mehran, R. and Chen, A.B. and Balter, P. and Wu, J. and Lee, J.J. and Sharma, P. and Heymach, J.},
title = {6-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non–Small Cell Lung Cancer: Randomized I-SABR Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S39--S40},
doi = {10.1016/j.ijrobp.2026.06.010}
}
EUVIMED